An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)

被引：0
|
作者：
Domchek, Susan M.
Postel-Vinay, Sophie
Bang, Yung-Jue
Park, Yeonh H.
Alexandre, Jerome
Delord, Jean-Pierre
Italiano, Antoine
You, Benoit
Bastian, Sara
Krebs, Matthew
Wang, Ding
Waqar, Saiama
Angell, Helen
Learoyd, Maria
Chang, Shao-Chun
Gresty, Christopher
Herbolsheimer, Pia
Kaufman, Bella
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Seoul Natl Univ Hosp, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[5] Cochin Hosp, Paris, France
[6] Inst Claudius Regaud Oncopole, Toulouse, France
[7] Inst Bergonie, Bordeaux, France
[8] Lyon Sud Univ, Lyon, France
[9] Kantonsspital Graubunden, Chur, Switzerland
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Henry Ford Hosp, Detroit, MI 48202 USA
[12] Washington Univ, Sch Med, St Louis, MO USA
[13] AstraZeneca, Cambridge, England
[14] AstraZeneca, Gaithersburg, MD USA
[15] Sheba Med Ctr, Ramat Gan, Israel
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD6-11
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S. M.
    Postel-Vinay, S.
    Im, S-A
    Park, Y. Hee
    Delord, J-P
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Tang, M.
    Gresty, C.
    Opincar, L.
    Herbolsheimer, P.
    Kaufman, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Im, Seock-Ah
    Park, Yeon Hee
    Delord, Jean-Pierre
    Italiano, Antoine
    Alexandre, Jerome
    You, Benoit
    Bastian, Sara
    Krebs, Matthew G.
    Wang, Ding
    Waqar, Saiama N.
    Lanasa, Mark
    Rhee, Joon
    Gao, Haiyan
    Rocher-Ros, Vidalba
    Jones, Emma, V
    Gulati, Sakshi
    Coenen-Stass, Anna
    Kozarewa, Iwanka
    Lai, Zhongwu
    Angell, Helen K.
    Opincar, Laura
    Herbolsheimer, Pia
    Kaufman, Bella
    LANCET ONCOLOGY, 2020, 21 (09): : 1155 - 1164
  • [3] Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S.
    Postel-Vinay, S.
    Im, S-A.
    Park, Y. H.
    Delord, J-P.
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Wang, D.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Lai, Z.
    Gresty, C.
    Opincar, L. M.
    Herbolsheimer, P.
    Kaufman, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 477 - 477
  • [4] Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
    Angell, Helen
    Ros, Vidalba Rocher
    Standifer, Nathan
    Lai, Zhongwu
    Gresty, Christopher
    Delord, Jean-Pierre
    De Jonge, Maja
    Postel-Vinay, Sophie
    Italiano, Antoine
    Krebs, Matthew G.
    Kaufman, Bella
    Park, Yeon Hee
    Domchek, Susan
    Herbolsheimer, Pia
    Hodgson, Darren
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    de Jonge, M.
    Hong, S. H.
    Park, Y. H.
    Wolfer, A.
    Brown, J.
    Ferguson, M.
    Gore, M. E.
    Alvarez, R. H.
    Gresty, C.
    Angell, H.
    Meyer, K.
    Learoyd, M.
    Tang, M.
    Lanasa, M.
    Herbolsheimer, P.
    Domchek, S. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 246 - 247
  • [6] An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC
    Krebs, M.
    Ross, K.
    Kim, S.
    De Jonge, M.
    Barlesi, F.
    Postel-Vinay, S.
    Domchek, S.
    Lee, J.
    Angell, H.
    Bui, K.
    Chang, S.
    Gresty, C.
    Herbolsheimer, P.
    Delord, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2043 - S2044
  • [7] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
    McCrea, Charles
    Hettle, Robert
    Gulati, Poonam
    Taneja, Ankush
    Rajora, Preety
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
  • [8] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
    Bang, Yung-Jue
    Kaufman, Bella
    Geva, Ravit
    Stemmer, Salomon M.
    Hong, Sook-Hee
    Lee, Jong-Seok
    Domchek, Susan M.
    Lanasa, Mark C.
    Tang, Mei
    Gresty, Christopher
    Angell, Helen K.
    Opincar, Laura L. M.
    Herbolsheimer, Pia Maarit
    Evans, T. R. Jeffry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).
    Meisner, Eleanor
    Rollins, Rebecca
    Ensor, Joe
    Moran, Amber
    Woodward, Amanda
    Ahn, Eugene R.
    Lynch, Cynthia Anne
    Citrin, Dennis L.
    Hansra, Damien
    Aithal, Sramila S.
    Ninan, Mary
    Nixon, Daniel W.
    Zook, Susan
    Ali, Siraj Mahamed
    Markman, Maurie
    Alvarez, Ricardo H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
12345